Bristol Gives Up On Adjuvant Melanoma For Opdualag With Failed Trial

The checkpoint inhibitor combo missed a recurrence-free survival endpoint in Phase III in post-surgical melanoma. The LAG-3 inhibitor-containing product continues development in lung cancer, however.